Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02470689
Other study ID # TASMC-15-SE-135-14-CTIL
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received May 27, 2015
Last updated June 9, 2015
Start date June 2015

Study information

Verified date May 2015
Source Tel-Aviv Sourasky Medical Center
Contact Dvora Cohen, M.A
Phone 972-3-6973768
Email dvorac@tlvmc.gov.il
Is FDA regulated No
Health authority Israel: Ethics Commission
Study type Interventional

Clinical Trial Summary

Epidermolysis bullosa simplex type Dowling-Meara (EBS-DM) is one of the most severe subtypes of EBS. Blisters and erosions of the skin and mucous membranes upon minor trauma are the consequence of dominantly inherited mutations in either the keratin 5 (K5) or keratin 14 (K14) gene, which encode proteins constituting the intermediate filament (IF) network in basal keratinocytes . Autosomal dominant mutations lead to a conformational change and an increased self-aggregation of the protein. Upon stress, aggregates present in the periphery of the cytoplasm, subsequently leading to the disintegration and collapse of the IF network. Clinically, patients suffer from blistering of the skin and mucous membranes upon minor trauma, resulting in an impaired life quality due to pain and pruritus . In vitro studies on Dowling-Meara keratinocytes revealed a significant upregulation of the pro-inflammatory cytokine interleukin-1beta (IL-1ß). Apart from paracrine effects of IL-1ß upon wounding (e.g. attraction of lymphocytes, activation of dermal fibroblasts), IL-1ß also activates keratinocytes via the cjun N-terminal kinase (JNK) stress pathway. The activation of this pathway leads to the activation of a number of transcription factors and the enhanced transcription of a number of genes, like matrix metalloproteinases, kallikreins, but also IL-1ß itself and K14 . Interestingly, this state of activation is constitutive and was also found in keratinocytes from non-lesional sites. It seems that the upregulation of IL-1ß and K14 in the presence of dominant Dowling-Meara mutations, results in a positive feedback loop, potentially aggravating the EBS-DM phenotype. This was strongly corroborated by the fact that when impairing IL1ß signaling, using IL-1ß neutralizing antibody (IL-1Ab) or the small molecule diacerein, expression levels of IL-1ß and K14 decreased and keratinocytes were much less susceptible to heat shock in vitro . Furthermore, activation levels of JNK widely correlated with expression levels of K14 and IL-1ß. (Wally V et al, 2013). These findings led to the hypothesis that blocking IL-1ß will also lead to an amelioration of the EBSDM phenotype in effected patients. Based on previous in vitro findings diacerein was chosen to be topically applied in a pilot study with five patients suffering from EBS-DM. In that study , each participant received 1% diacerein-cream for one armpit, and placebo for the other (randomized withdrawal). The number of blisters was reduced significantly (left: -78%; right: -66% of baseline) within two weeks and remained significantly below the initial level even during withdrawal in four patients. These findings pointed to a relevant effect of diacerein and provide important information for our confirmative study.

Diacerein is a component of the rhubarb root, which is reported to block the release of active IL-1b by inhibiting plasma membrane-bound IL-1 converting enzyme . Diacerien is already approved for systemic application in osteoarthritis . In general, small molecules (SM) are low molecular weight compounds with biological functions that can influence molecular processes. They allow a symptomatic treatment, offering a short-term benefit for patients in terms of an amelioration of the phenotype. Although this kind of treatment does not correct genetic alterations, it can still be highly beneficial by damping down disease symptoms, thereby increasing life quality and minimizing secondary manifestations.

It is important to emphasize that besides dressings, there are currently no other treatments, therefore, investigators do not prevent an accepted treatment for the patient and there is no risk for the participant. The treatment will be given only to the armpits although the disease can involve other areas, so stopping dressings in the armpits during the study does not risk the patient. Should there be any deterioration of the patient, whether it is related to the treatment with diacerein or not, investigators will stop the use of diacerein.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender Both
Age group 6 Years to 19 Years
Eligibility Inclusion Criteria:

1. Diagnosis of EBS-DM

2. An age between 6 - 19

Exclusion Criteria:

1. Lack of mutation analysis

2. Intolerance to a component of the cream

3. Pregnancy or Lactation

4. Contemporaneous participation in another clinical trial

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Diacerin cream
Diacerin tablet solubule in ultraphil cream

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Tel-Aviv Sourasky Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary Number of blisters 4 weeks Yes
Secondary Number of blisters 3 months period Yes
See also
  Status Clinical Trial Phase
Completed NCT02592954 - Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin Phase 1
Recruiting NCT03269474 - Computational Drug Repurposing for All EBS Cases
Completed NCT05062070 - Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex Phase 1
Recruiting NCT03016715 - Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study Phase 2
Completed NCT02960997 - Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study Phase 2
Recruiting NCT00936533 - Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita Phase 2
Completed NCT03472287 - To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB) Phase 1
Recruiting NCT04213703 - A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
Recruiting NCT03453632 - Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex Phase 2/Phase 3
Terminated NCT03154333 - Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS) Phase 2
Active, not recruiting NCT05033574 - The State of Sexual Development in Children With Inherited Epidermolysis Bullosa
Completed NCT04908215 - INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa Phase 2
Completed NCT03389308 - Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex Phase 2